BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:roginolisib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of roginolisib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06879717-2712@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:roginolisib: Phase 1/2 readout est. (NCT06879717)
DESCRIPTION:roginolisib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Wi
 thout Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/roginolisib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06879717
URL:https://assetmemo.bio/drug/roginolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07847957-2712@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:roginolisib: Phase 1/2 readout est. (NCT07847957)
DESCRIPTION:roginolisib\, phase 1/2.\nStudy: Roginolisib Plus Obinutuzumab 
 + Venetoclax in R/R CLL\nEstimated primary completion: 1 April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/roginolisib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07847957
URL:https://assetmemo.bio/drug/roginolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717126-2712@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:roginolisib: Phase 2 readout est. (NCT06717126)
DESCRIPTION:roginolisib\, phase 2\, Uveal Melanoma.\nStudy: A Randomised Ph
 ase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Mel
 anoma\nEstimated primary completion: December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/roginolisib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06717126
URL:https://assetmemo.bio/drug/roginolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203391-2712@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:roginolisib: Phase 1 readout est. (NCT07203391)
DESCRIPTION:roginolisib\, phase 1\, Uveal Melanoma.\nStudy: Tebentafusp and
  Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis\nEstimated pr
 imary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/roginolisib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07203391
URL:https://assetmemo.bio/drug/roginolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887803-2712@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:roginolisib: Phase 1/2 readout est. (NCT06887803)
DESCRIPTION:roginolisib\, phase 1/2.\nStudy: A Study of Roginolisib in Comb
 ination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unres
 ponsive to JAK Inhibitors\nEstimated primary completion: March 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/roginolisib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06887803
URL:https://assetmemo.bio/drug/roginolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018752-2712@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:roginolisib: Phase 1/2 readout est. (NCT07018752)
DESCRIPTION:roginolisib\, phase 1/2.\nStudy: A Platform Trial Evaluating Ne
 w Drugs or Combination in R/R Peripheral T-cell Lymphomas\nEstimated prima
 ry completion: April 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/roginolisib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07018752
URL:https://assetmemo.bio/drug/roginolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644183-2712@assetmemo.bio
DTSTAMP:20261121T004523Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:roginolisib: Phase 1/2 readout est. (NCT06644183)
DESCRIPTION:roginolisib\, phase 1/2.\nStudy: Roginolisib (IOA-244) With Ven
 etoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia
  (CLL)\nEstimated primary completion: 1 October 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/roginolisib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06644183
URL:https://assetmemo.bio/drug/roginolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
